Leukemia Clinical Trials

57 studies are recruiting for leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Boston, Massachusetts 16 Houston, Texas 11 New York, New York 9 Chicago, Illinois 7 Chapel Hill, North Carolina 6 Los Angeles, California 5 Milwaukee, Wisconsin 5 Omaha, Nebraska 5 Seattle, Washington 5 Aurora, Colorado 4 Buffalo, New York 4 Duarte, California 4 Miami, Florida 4 Nashville, Tennessee 4 Philadelphia, Pennsylvania 4 Basking Ridge, New Jersey 3 Bethesda, Maryland 3 Birmingham, Alabama 3 Charlotte, North Carolina 3 Cincinnati, Ohio 3 Columbus, Ohio 3 Commack, New York 3 Harrison, New York 3 Memphis, Tennessee 3 Middletown, New Jersey 3 Orange, California 3

Studies now recruiting

  1. Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

    This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not r…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Weill Cornell, New York, New York
    Locations
    64 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT06824168 on ClinicalTrials.gov

  2. A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

    This is a single-arm pilot clinical trial evaluating dalbavancin-based prophylaxis in children and adolescents with acute myeloid leukemia or relapsed lymphoblastic leukemia receiving myelosuppressive chemotherapy. Primary objective: - To estimate the rate of bacterial bloodstream infection in pedi…

    Stage
    Phase 1
    Ages
    Up to 25
    Site
    St. Jude Children's Research Hospital, Memphis, Tennessee
    Run by
    St. Jude Children's Research Hospital

    See if you can join NCT06810583 on ClinicalTrials.gov

  3. A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

    To learn if revumenib (also known as SNDX-5613) can help to control leukemias associated with an increase in expression of HOX genes.

    Stage
    Phase 2
    Ages
    12 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    2 in total
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT06229912 on ClinicalTrials.gov

  4. Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

    This study aims to test the Tools for Reducing Inequity in Acute Leukemia (TRIAL) web-based application that is designed to support participants with acute leukemia by providing information and resources about leukemia and clinical trial participation.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT06907797 on ClinicalTrials.gov

  5. Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

    This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The University of Alabama at Birmingham, Birmingham, Alabama
    Locations
    3 in total
    Run by
    Hannah Choe, MD

    See if you can join NCT07249346 on ClinicalTrials.gov

  6. Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

    The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusion of a commercial CAR called Tisagenlecleucel, to…

    Stage
    Phase 1
    Ages
    1 to 25
    Site
    Stanford University, Palo Alto, California
    Run by
    Stanford University

    See if you can join NCT06408194 on ClinicalTrials.gov

  7. Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

    Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically in…

    Stage
    Not phased
    Ages
    5 and older
    Site
    Children s Hospital of Los Angeles, Los Angeles, California
    Locations
    3 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT05237986 on ClinicalTrials.gov

  8. CIML NK Cells With Venetoclax for AML

    The purpose of this research study is to test the safety and to explore the effectiveness of infusing cytokine- induced memory-like (CIML) natural killer (NK) cells in combination with Interleukin-2 (IL-2) and standard-of-care venetoclax as a treatment for Acute Myeloid Leukemia (AML) with measurab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Brigham and Women's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT06152809 on ClinicalTrials.gov

  9. Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

    This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combination venetoclax and azacitidine in participants with acute myeloid leukemia (AML). The names of the study drugs involved in this research …

    Stage
    Phase 1
    Ages
    18 to 90
    Site
    Brigham and Women's Hospital, Boston, Massachusetts
    Locations
    2 in total
    Run by
    Jacqueline Garcia, MD

    See if you can join NCT07439211 on ClinicalTrials.gov

  10. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Banner MD Anderson Cancer Center, Gilbert, Arizona
    Locations
    45 in total
    Run by
    Kura Oncology, Inc.

    See if you can join NCT06001788 on ClinicalTrials.gov

  11. Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

    Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Age is a risk factor for Alzheimer's…

    Stage
    Not phased
    Ages
    19 and older
    Site
    University of Nebraska Medical Center, Omaha, Nebraska
    Run by
    University of Nebraska

    See if you can join NCT04898790 on ClinicalTrials.gov

  12. ALL Backbone in AYAs

    The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs). The names of the study drugs involved in this study are: * blinatumomab (a type of …

    Stage
    Phase 2
    Ages
    18 to 51
    Site
    Dana Farber Cancer Institute, Boston, Massachusetts
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT07227584 on ClinicalTrials.gov

  13. DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

    The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatm…

    Stage
    Not phased
    Ages
    60 and older
    Site
    Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06296368 on ClinicalTrials.gov

  14. Mosaic Trial for Stem Cell Transplant Recipients

    The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recru…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Georgetown University School of Medicine, Washington D.C., District of Columbia
    Locations
    3 in total
    Run by
    Northwestern University

    See if you can join NCT06960993 on ClinicalTrials.gov

  15. Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)

    Acute lymphoblastic leukemia (ALL) is the most common cancer in children and, along with lymphoblastic lymphoma, represents the most common group of childhood lymphoid malignancies. Survival rates have improved over the years, but many children still experience long-term side effects from treatment…

    Stage
    Not phased
    Ages
    6 and older
    Site
    University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07634653 on ClinicalTrials.gov

  16. Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

    To learn if cyclophosphamide, vincristine, and dexamethasone (called mini hyper-CVD) in combination with intrathecal (delivered into the spine) chemotherapy (methotrexate, hydrocortisone, cytarabine) and compressed rituximab, blinatumomab, and inotuzumab ozogamicin (called cRIB) can help to control…

    Stage
    Phase 2
    Ages
    1 to 25
    Site
    M D Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT05645718 on ClinicalTrials.gov

  17. Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

    The goal of this clinical research study is to learn if cladribine given in combination with low-dose cytarabine (LDAC) and decitabine can help control the disease in patients with AML or MDS. The safety of this drug combination will also be studied. Cladribine is designed to interfere with the cel…

    Stage
    Phase 2
    Ages
    60 and older
    Site
    University of Texas MD Anderson Cancer Center, Houston, Texas
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT01515527 on ClinicalTrials.gov

  18. Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

    This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and…

    Stage
    Not phased
    Ages
    Up to 30
    Site
    Connecticut Children's Medical Center, Hartford, Connecticut
    Locations
    8 in total
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT04968834 on ClinicalTrials.gov

  19. Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

    The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Run by
    Dana-Farber Cancer Institute

    See if you can join NCT06469307 on ClinicalTrials.gov

  20. Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

    This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole bra…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California
    Run by
    University of California, Irvine

    See if you can join NCT06580002 on ClinicalTrials.gov

  21. Pre-malignant States to Hematologic Malignancies in Firefighters

    The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.

    Stage
    Not phased
    Ages
    40 to 49
    Site
    Levine Cancer Institute, Charlotte, North Carolina
    Run by
    Wake Forest University Health Sciences

    See if you can join NCT06870760 on ClinicalTrials.gov

  22. Halt Aging in Survivors of Blood Cancers

    Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting th…

    Stage
    Not phased
    Ages
    50 and older
    Site
    University of Nebraska Medical Center, Omaha, Nebraska
    Run by
    University of Nebraska

    See if you can join NCT07292272 on ClinicalTrials.gov

  23. Registry of Older Patients With Cancer

    RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.

    Stage
    Not phased
    Ages
    65 and older
    Site
    Seby B. Jones Cancer Center, Boone, North Carolina
    Locations
    7 in total
    Run by
    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT01137825 on ClinicalTrials.gov

  24. Integrated Cancer Repository for Cancer Research

    The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct char…

    Stage
    Not phased
    Ages
    19 to 110
    Site
    Advent Health, Greenwood Village, Colorado
    Locations
    42 in total
    Run by
    University of Nebraska

    See if you can join NCT02012699 on ClinicalTrials.gov

  25. A Study of Revumenib and Mezigdomide in People With Leukemia

    The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey
    Locations
    10 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07356154 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.